References to Primary Literature
- Tatemoto, K Neuropeptide Y: Complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. USA 1982 72 5485–5489.
- Edvinsson, L Hakanson, R Wahlestedt, C Uddman, R Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol. Sci. 1987 8 231–235.
- Balasubramaniam, A Sheriff, S Neuropeptide Y (18–36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes. J. Biol. Chem. 1990 265 14724–14727.
- Michel, MC Schlicker, E Fink, K Boublik, JH Göthert, M Willette, RN Daly, RN Hieble, JP Rivier, JE Motulsky, HJ Distinction of NPY receptors in vitro and in vivo. I. NPY-(18–36) discriminates NPY receptor subtypes in vitro. Am. J. Physiol. 1990 259 E131–E139.
- Tatemoto, K Neuropeptide Y and its receptor antagonists. Use of an analog mixture-screening strategy. Ann. N.Y. Acad. Sci. 1990 611 1–6.
- Dougherty, MB Chu, SS Miller, DW Li, K Tessel, RE Benextramine: A long-lasting neuropeptide Y receptor antagonist. Eur. J. Pharmacol. 1990 185 113–114.
- Michel, MC Motulsky, HJ He 90481: A competitive nonpeptidergic antagonist at neuropeptide Y receptors. Ann. N.Y. Acad. Sci. 1990 611 392–394.
- Edvinsson, L Adamsson, M Jansen, I Neuropeptide Y antagonistic properties of D-myo-inositol-1.2.6-trisphosphate in guinea pig basilar arteries. Neuropeptides 1990 17 99–105.
- Adamsson, M Edvinsson, L Blockade of neuropeptide Y-induced potentiation of nor-adrenaline-evoked vasoconstriction by D-myo-inositol-1.2.6-trisphosphate (PP56) in rabbit femoral arteries. Neuropeptides 1991 19 13–16.
- Adamsson, M Fallgren, B Edvinsson, L Inhibition of neuropeptide Y-induced potentiation of noradrenaline-induced vasoconstriction by PP56 (d-myo-inositol-1,2,6-tris-phosphate). Br. J. Pharmacol. 1992 105 93–96.
- Edvinsson, L Adamsson, M Neuropeptide Y inhibits relaxation of guinea pig cerebral, coronary and uterine arteries: Blockade by D-myo-inositol-1,2,6-trisphosphate. J. Cardiovasc. Pharmacol 1992 In press.
- Edvinsson, L Adamsson, M Andersson, D Hedner, T Sun, X Fellström, B Sirén, M Larhammar, D Reis, DJ Yoo, H Walhlestedt, C D-myo-inositol-[1,2,6]-trisphosphate: A functional (non-receptor) neuropeptide Y (NPY) antagonist in vasculature Proc. Natl. Acad. Sci. USA 1992 In press.
- Heilig, M Edvinsson, L Wahlestedt, C Effects of intracerebroventricular D-myo-inositol-1,2,6-trisphosphate (PP56), a proposed neuropeptide Y (NPY) antagonist, on locomotor activity, food intake, central effects of NPY and NPY receptor binding. Eur. J. Pharmacol. 1991 209 27–32.
- Sun, X Dahlóf, C Edvinsson, L Hedner, T D-myo-inositol-1,2,6-trisphosphate is a selective antagonist of neuropeptide Y-induced pressor responses in the pithed rat. Eur. J. Pharmacol. 1991 204 281–286.
- Reddy, NR Sathe, SK Salunkhe, DK Phytates in legumes and cereals. Adv. Food Res. 1982 28 1–92.
- Maga, JA Phytate: Its chemistry, occurrence in food, interactions, nutritional significance, and methods of analysis. J. Agric. Food Chem. 1982 30 1–9.
- Loewus, FA Phytate metabolism with special reference to its myo-inositol component. Recent Adv. Phytochem. 1982 17 173–192.
- Szwergold, BS Graham, RA Brown, TR Observation of inositol pentakis- and hexakis- phosphates in mammalian tissues by 31P-NMR. Biochem. Biophys. Res. Comm. 1987 149 874–881.
- Hawkins, PT Reynolds, DJM Poyner, DR Hanley, MR Identification of a novel inositol phosphate recognition site: Specific 3H-inositol hexakisphosphate binding to brain regions and cerebellar membranes. Biochem. Biophys. Res. Comm. 1990 167 819–827.
- Fallgren, B Arlock, P Jansen, I Edvinsson, L Neuropeptide Y in cerebrovascular function: Comparison of membrane potential changes and vasomotor responses evoked by NPY and other vasoconstrictors in the guinea pig basilar artery. Neurosci Lett. 1989 114 117–122.
- Edvinsson, E Copeland, JR Emson, PC McCulloch, J Uddman, R Nerve fibers containing neuropeptide Y in the cerebrovascular bed: Immunocytochemistry, radioimmunoassay, and vasomotor effects. J. Cereb. Blood Flow Metab. 1987 7 45–57.
- Wahlestedt, C Edvinsson, L Ekblad, E Hakanson, R Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: Mode of action. J. Pharmacol. Exp. Ther. 1985 234 735–741.
- Johansson, H Cytoplasmic Ca2+ concentration of single normal human and bovine parathyroid cells measured by dual wavelength microfluorometry. Biosci. Rep. 1987 7 705–712.
- Grynkiewicz, G Poenie, M Tsien, RY A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985 260 3440–3450.
- Fredholm, BB Jansen, I Edvinsson, L Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Acta Physiol. Scand. 1985 124 467–469.
- Wahlestedt, C Grundemar, L Hakanson, R Heilig, M Shen, GH Zukowska-Grojec, Z Reis, DJ Neuropeptide Y receptor sub-types, Y1 and Y2. Ann. N.Y. Acad. Sci. 1990 611 7–26.
- Mihara, S Shigeri, Y Fujimoto, M Neuropeptide Y-induced intracellular Ca2+ increase in vascular smooth muscle cells. FEBS Lett. 1989 H259 79–82.
- Authi, KS Gustafsson, TO Crawford, N The effect of inositol (1,2,6) trisphosphate (PP56) on the calcium sequestration properties of human platelets. Trombosis Haemostrasis 1989 62 250.
- Edvinsson, L Ekman, R Thulin, T Increased plasma levels of neuropeptide Y-like immuno-reactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regulat. Pept. 1991 32 279–287.
References to Patent literature
- Heumann Pharma GmbH EP -448765-A.
- Merrell Dow EP -439174-A.
- Salk Inst Biological Studies US 5026685.
- Basf AG WO 9108223.
- Merrell Dow EP -355794-A.
- Merrell Dow EP -355793-A.
- Boehringer Ingelheim DE 3811193.
- Debiopharm SA US 48339343.
- University of Florida US 4891357.
- Perstorp Pharma WO 9200079.